Fig. 3: This figure shows patients acheiving a deep light chains suppresion (dFLC <10 mg/L or iFLC <20 mg/L) and outcomes stratified by deep light chain suppression (or not).
From: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
A Shows the distribution of patients with CR/VGPR and deep FLC suppression (dFLC < 10 mg/l or iFLC < 20 mg/l) at 1 and 6 months. At 1 month, 60.6% and 39.3% patients with CR and VGPR had dFLC < 10 mg/l, respectively. The corresponding figures at 6 months were 85.7% and 48.6%, respectively. 34.3% and 33% of patients with CR and VGPR had iFLC < 20 mg/l at 1 month. The corresponding figure at 6 months is 60.2% and 35%, respectively. B Kaplan–Meier curve showing the impact of low iFLC (< 20 mg/l) on patients with CR at 1-month. Patients with CR and iFLC < 20 mg/l at 1-month had significantly better survival compared to patients with CR and iFLC > 20 mg/l- median not reached in both groups (p = 0.005). C Kaplan–Meier curve showing the impact of dFLC < 10 mg/l in patients with CR/VGPR at 6 months. There was no significant difference in survival between patients with CR + dFLC < 10 mg/l and VGPR + dFLC < 10 mg/l—median not reached in both groups (p = 0.693). Patients with VGPR + dFLC < 10 mg/l had a significantly better survival when compared to patients with CR and dFLC > 10 mg/l (p = 0.002)—median not reached vs. 72 months (95% CI 38.94–105.05 months). There was no significant difference in survival between patients with CR + dFLC > 10 mg/l and VGPR + dFLC > 10 mg/l (p = 0.454)—median 72 months (95% CI 38.94–105.05 months) vs. 61 months (95% CI 38.07-83.93 months). D Kaplan–Meier curve showing the impact of iFLC < 20 mg/l in patients with CR/VGPR at 6 months. There was no significant difference in survival between patients with CR + iFLC < 20 mg/l and VGPR + iFLC < 20 mg/l—median not reached in both groups (p = 0.683). Patients with VGPR + iFLC < 20 mg/l had a significantly better survival when compared to patients with CR and iFLC > 20 mg/l (p = 0.005)—median not reached vs. 74 months (95% CI 65.60–82.40). There was no significant difference in survival between patients with CR + iFLC > 20 mg/l and VGPR + iFLC > 20 mg/l (p = 0.818)—median 74 months (95% CI 65.60–82.40) vs. 65 months (95% CI 46.81–83.18 months).
